Aegis Capital analyst Nathan Weinstein maintained a Buy rating on Acasti Pharma, Inc. (ACST) today and set a price target of $3. The company’s shares opened today at $1.46.
Weinstein said:
“We are launching coverage on ACST with a buy rating and $3.00 PT and we believe Acasti will endeavor to advance towards commercializing CaPre potentially as early as 2021.”
According to TipRanks.com, Weinstein is ranked #4168 out of 5237 analysts.
Acasti Pharma, Inc. has an analyst consensus of Moderate Buy.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.80 and a one-year low of $0.43. Currently, Acasti Pharma, Inc. has an average volume of 643.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acasti Pharma, Inc. engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland on February 1, 2002 and is headquartered in Laval, Canada.
